Oral contraceptives: Risks

Obstetrics and Gynecology Clinics of North America

Volumn 27, Issue 4, 2000, Pages 695-704

  Shulman, Lee P ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

BREAST CANCER; CANCER RISK; CEREBROVASCULAR ACCIDENT; CONTRACEPTION; DRUG SAFETY; FEMALE; GENITAL TRACT CANCER; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM;

EID: 0033757526     PISSN: 08898545     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8545(05)70168-6     Document Type: Article

References (36)

1. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age
2. Breast cancer and hormonal contraceptives: Collaborative breast cancer reanalysis of individual data on 53,297 women with the 100,239 women without breast cancer from 54 epidemiological studies
3. Screening for factor V Leiden mutation before prescribing combination oral contraceptives
4. Risk factors for acute myocardial infarction in women: Evidence from the Royal College of General Practitioners' oral contraception study
5. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to protein C
6. Population-based study of risk of venous thromboembolism associated with various oral contraceptives
7. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
8. The estimated effect of oral contraceptive use on the cumulative risk of epithelial ovarian cancer
9. Oral contraception and stroke: Evidence from the Royal College of General Practitioners' oral contraception study
10. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components
11. Patient education and understanding: A critical review
12. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study
13. The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research
14. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 and 30 mcg oestrogen preparations
15. Haemostatic, lipid and blood-pressure profiles of women on oral contraceptives containing 50 mcg or 30 mcg oestrogen
16. Oral contraceptives: Indications, contraindications, formulations and monitoring
17. Oral contraceptives and the risk of hereditary ovarian cancer
18. Oral contraceptive risk assessment: A survey of 247 educated women
19. Stroke in users of low-dose oral contraceptives
20. Incidence of stroke and myocardial infarction in women of reproductive age
21. Oral contraceptive use and the risk of myocardial infarction
22. Case-control study of oral contraceptive use and risk of breast cancer
23. Evidence based medicine: What it is and what it isn't. It's about integrating individual clinical expertise and the best external evidence
24. Myocardial infarction in users of low-dose oral contraceptives
25. Myocardial infarction and use of low-dose oral contraceptives: A pooled analysis of 2 US studies
26. Risk of endometrial cancer in relation to use of combined oral contraceptives: A practitioner's guide to meta-analysis
27. Stroke and use of low-dose oral contraceptives in young women: A pooled analysis of two US studies
28. Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study
29. Resistance to activated protein C as a basis for venous thrombosis
30. Perceptions of contraceptive effectiveness and health effects of oral contraception
31. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women?
32. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation
33. Acute myocardial infarction and combined oral contraceptives: Results of an international multicentre case-control study
34. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease
35. Cardiovascular disease and steroid contraception